Table 1.
Summary of prevalence of serological anti-SARS-CoV-2 antibodies evaluated by Elecsys Anti-SARS-CoV-2 Assay and Academia Sinica ELISA assay categorized by age and sex
|
Number of samples |
Proportion of sample, % |
Elecsys screening Positive |
ELISA confirmatory Positive (IgG/IgM) |
Proportion of ELISA Positive, % (95% CI) |
Relative risk (95% CI) |
p value | |
|---|---|---|---|---|---|---|---|
| Total | 14765 | 100 | 25 | 11 (7 / 4) | 0•07 (0•04-0•13) | •• | •• |
| Age, years | |||||||
| 20-29 | 617 | 4•18 | 0 | 0 (0 / 0) | 0•00 (0•00-0•60) | 1•52 (0•06-37•35) | 0•796 |
| 30-39 | 1070 | 7•25 | 1 | 1 (0 / 1) | 0•09 (0•00-0•52) | 2•64 (0•17-42•14) | 0•493 |
| 40-49 | 1536 | 10•40 | 3 | 1 (0 / 1) | 0•07 (0•00-0•36) | 1•84 (0•12-29•36) | 0•667 |
| 50-59 | 2762 | 18•71 | 5 | 1 (1 / 0) | 0•04 (0•00-0•20) | 1•02 (0•06-16•33) | 0•988 |
| 60-69 | 3847 | 26•05 | 7 | 4 (3 / 1) | 0•10 (0•03-0•27) | 3•24 (0•36-28•96) | 0•293 |
| 70-79 | 2823 | 19•12 | 4 | 1 (1 / 0) | 0•04 (0•00-0•20) | 1 (ref) | •• |
| 80-89 | 1546 | 10•47 | 3 | 1 (0 / 1) | 0•06 (0•00-0•36) | 1•83 (0•11-29•17) | 0•670 |
| ≥90 | 564 | 3•82 | 2 | 2 (2 / 0) | 0•35 (0•04-1•27) | 10•01 (0•91-110•22) | 0•060 |
| Sex | |||||||
| Male | 7290 | 49•37 | 15 | 7 (5 / 2) | 0•10 (0•04-0•20) | 1•79 (0•53-6•13) | 0•351 |
| Female | 7475 | 50•63 | 10 | 4 (2 / 2) | 0•05 (0•01-0•14) | 1 (ref) | •• |
Female and age 70-79 years groups are used as the reference for relative risk calculation, respectively, to which other groups are compared.
95% confidence intervals are estimated using exact binomial models.